Breaking News
April 19, 2019 - New insights into how vitamin D affects immune system
April 19, 2019 - Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
April 19, 2019 - Exercise can improve non-motor symptoms of Parkinson’s disease
April 19, 2019 - KZFPs play a key role in the regulation of human genome
April 19, 2019 - Extracts of ginkgo seeds show antibacterial activity on pathogens that cause skin infections
April 19, 2019 - Exercises and swimming goggles may reduce adverse effects on eye during long spaceflights
April 19, 2019 - Review suggests a reciprocal relationship between obesity and self-control
April 19, 2019 - Study identifies how enterococci bacteria cause antibiotic-resistant bloodstream infections
April 19, 2019 - Triple negative breast cancer develop resistance to chemotherapy by turning on molecular pathway
April 19, 2019 - Researchers identify key clues to brain and pancreas development
April 19, 2019 - Metformin May Cut Risk for Prematurity, Miscarriage in PCOS
April 19, 2019 - Obese mouse mothers trigger heart problems in offspring
April 19, 2019 - Research sheds light on how leukemia cells become resistant to drugs
April 19, 2019 - Health Tip: Stopping Nosebleeds – Drugs.com MedNews
April 19, 2019 - Pediatric endocrinologist gives iconic ‘Mona Lisa’ a second medical opinion
April 19, 2019 - Tapping patients’ wisdom for C-section pain management
April 18, 2019 - Why have autism rates ‘exploded’ in New Jersey?
April 18, 2019 - Microbiome science may help doctors to improve treatment for children with IBS
April 18, 2019 - New gene therapy cures babies with fatal ‘Bubble Boy’ disease
April 18, 2019 - No female mice? Scientists may still approve NIH grant
April 18, 2019 - What needs to be said about mental health in medicine
April 18, 2019 - Hickenlooper Expanded Medicaid, Created State-Run Marketplace To Insure Nearly All Coloradans
April 18, 2019 - Cancer cells grown in tumor-mimicking environment can help predict the effect of experimental drugs
April 18, 2019 - Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
April 18, 2019 - Adhesive gel bonds to eye surface, could repair injuries without surgery
April 18, 2019 - The future of genomics: A podcast featuring Stanford geneticists
April 18, 2019 - As Syphilis Invades Rural America, A Fraying Health Safety Net Is Failing To Stop It
April 18, 2019 - APOE gene impacts sleep depending on gender and severity of Alzheimer’s
April 18, 2019 - PCORI’s newly approved awards focus on cancer pain and opioid use disorders
April 18, 2019 - New tool provides a standard way to measure effects of caring for survivors of TBI
April 18, 2019 - Smartphone use risks eye examination misdiagnosis
April 18, 2019 - How drug-resistant bugs grow in CF patients’ lungs
April 18, 2019 - Gordana Vunjak-Novakovic Elected to American Academy of Arts & Sciences
April 18, 2019 - Podcast: KHN’s ‘What The Health?’ You Have Questions, We Have Answers
April 18, 2019 - Diabetic drug shows potential to be repurposed as heart disease treatment for non-diabetic patients
April 18, 2019 - New estimation method assesses natural variations in sex ratio at birth
April 18, 2019 - UTA scientist receives $1.17 million grant for cancer research
April 18, 2019 - Coagulation factor VIIa prevents bleeds in hemophilia animal models
April 18, 2019 - Researchers identify risk factors for severe infection after knee replacement
April 18, 2019 - Mass drug administration can offer community-level protection against malaria
April 18, 2019 - FDA’s added sugar label could have substantial health and cost-saving benefits
April 18, 2019 - Researchers identify cause of inherited metabolic disorder
April 18, 2019 - Single strip of white paint not sufficient to protect people who ride bikes
April 18, 2019 - Partner status influences link between sexual problems and self-efficacy in breast cancer survivors
April 18, 2019 - Colorectal Neoplasia Risk Up for Hodgkin Lymphoma Survivors
April 18, 2019 - Rigid spine muscular dystrophy – Genetics Home Reference
April 18, 2019 - Simple bile acid blood test could tell risk of stillbirth
April 18, 2019 - Center for Experimental Therapeutics aims to enable all steps of drug development | News Center
April 18, 2019 - Falling for telephone scams could be an early sign of dementia
April 18, 2019 - Researchers annotate key neuronal proteins in lamprey genome
April 18, 2019 - Study uncovers new biomarker for personalized cancer treatments
April 18, 2019 - Scientists enter research collaboration to find a cure for cancer
April 18, 2019 - Study to compare benefits of tai chi and mindfulness meditation on MS symptoms
April 18, 2019 - Gestational diabetes during pregnancy may increase risk of type 1 diabetes in children
April 18, 2019 - Maternal age has no effect on IVF success, conclude researchers
April 18, 2019 - Is a New Remedy for Body Odor on the Horizon?
April 18, 2019 - Orthostatic hypotension – Genetics Home Reference
April 18, 2019 - Healing the heartbreak of stillbirth and newborn death
April 18, 2019 - New study calls healthiness of eggs into question
April 18, 2019 - Conference to highlight advances in human immune monitoring, bioinformatics | News Center
April 18, 2019 - Bacteria use viruses for self-recognition, study reveals
April 18, 2019 - New adhesive patch could help reduce post-heart attack muscle damage
April 18, 2019 - Researchers analyze the effects of dark play in a serious video game
April 18, 2019 - Scientists revive pig brain cells four hours after death
April 18, 2019 - Filial cannibalism and offspring abandonment may be forms of parental care
April 18, 2019 - Two proteins act in concert to maintain a healthy heart in mice, shows study
April 18, 2019 - Scientists create a functioning 3D printed heart
April 18, 2019 - Non-invasive vagus nerve stimulation improves disease symptoms in patients with rheumatoid arthritis
April 18, 2019 - Majority of men struggle to understand diagnosis and treatment of prostate cancer
April 18, 2019 - Researchers create new small molecules that may combat equine encephalitis viruses
April 18, 2019 - Animal-assisted therapy improves social behavior in patients with brain injuries
April 18, 2019 - Some viruses help protect harmful bacteria in CF patients | News Center
April 18, 2019 - Outpatient healthcare providers inappropriately prescribe antibiotics to 40% of patients
April 18, 2019 - Men who have a resting heart rate of 75 bpm are twice as likely to die early
April 18, 2019 - Novel serum biomarkers to detect NAFLD-related fibrosis
April 18, 2019 - New study delves deeper into individual genomic differences than ever before
April 18, 2019 - Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients
April 18, 2019 - Emotional mirror neurons found in rats
April 18, 2019 - Sylvia Plevritis appointed chair of biomedical data science | News Center
April 18, 2019 - Cervical cancer subtype increasing in several subpopulations of women
Barrow Institute initiates $50 million effort to seek cure for glioblastoma

Barrow Institute initiates $50 million effort to seek cure for glioblastoma

image_pdfDownload PDFimage_print

Barrow Neurological Institute has initiated a $50 million effort, supported by the single largest research grant in the history of brain tumor research, to seek a cure for the deadliest form of brain cancer. Funding from The Ben and Catherine Ivy Foundation will be used to dramatically accelerate drug discovery and clinical testing for glioblastoma in the newly-formed Ivy Brain Tumor Center at the Barrow Neurological Institute.

The Ivy Center will become a cornerstone at Barrow, which conducts more brain tumor operations than any hospital in the nation, and is part of Dignity Health St. Joseph’s Hospital and Medical Center. Already screening malignant brain tumor patients from around the world, the new Center will ultimately mean that every patient, regardless of diagnosis or state of the tumor, will have the individualized option for an experimental therapy.

“This grant will fast track discovery and offer support and hope to those battling glioblastoma and other malignant brain tumors,” says Nader Sanai, MD, director of neurosurgical oncology. Dr. Sanai is an internationally renowned pioneer in glioblastoma research and will head the new Center. “The formation of the Ivy Brain Tumor Center will propel our singular research strategy to a new level of personalized medicine as we put a laser focus on discovering a cure,” he said. “The Ivy Foundation’s commitment is a true gift of hope.”

Catherine Ivy, president of The Ben and Catherine Ivy Foundation, said the Center’s ultimate goal is to cure brain cancer. “The more we discover, the more we can do to help patients and their families. Our Foundation has partnered with renowned medical and research programs throughout the United States and even internationally,” she said. “After years of assessment, we have decided to invest in the Ivy Brain Tumor Center at Barrow. We think Barrow and the new Ivy Brain Tumor Center are our best bet. “

More than 138,000 Americans currently are living with a malignant brain tumor and more than nine out of 10 diagnosed with glioblastoma die within five years. Market forces and a string of high-profile clinical trial failures have led pharmaceutical firms to de-prioritize malignant brain tumor patients. Between 1998 and 2014, 78 investigational brain tumor drugs entered advanced clinical trial evaluation and 75 failed.

This lack of new drugs led Dr. Sanai in 2016 to launch a bold approach to treat glioblastoma with Barrow’s ‘Phase 0’ trials. In a Phase 0 trial, a patient receives a small dose of an experimental drug the day before surgery. During the operation, surgeons collect the patient’s samples and a team of scientists immediately test for the effectiveness of the drug. Results are available in days and, if the trial drug proves to be active, the patient goes on to receive aggressive treatment with higher doses. This approach is a unique form of personalized medicine and the first of its kind for brain tumor patients.

Prior to Barrow’s daring expansion into Phase 0 trialing, complex studies like this were only attempted at the National Institutes of Health. Now, Barrow is leading a national movement to rapidly identify new drugs that will save lives. “Phase 0 trials are the quickest route to identify individualized strategies for treating glioblastoma and our approach demands only a fraction of the time and costs associated with traditional drug research and development,” says Dr. Sanai. “With the Ivy Foundation’s grant and Barrow’s expertise in Phase 0 trialing, we believe glioblastoma will meet its match.”

The Ben and Catherine Ivy Foundation, based in Scottsdale, Ariz., is the largest non-governmental funding mechanism of brain tumor research in the world, having committed more than $123 million to patient-focused research on gliomas, a type of tumor that occurs in the brain and spinal cord. Ivy became involved in brain tumor research when her husband, Ben, lost his battle with glioblastoma in 2005.

“Thanks to the Ivy Foundation’s inspiring commitment, the Barrow Neurological Institute has established the Ivy Brain Tumor Center, a 15,000 square foot state-of-the-art facility that provides Dr. Sanai and his team of scientists and clinician specialists with state-of-the-art resources to focus on accelerated patient trials and save lives”, said Katie Cobb, president of the Barrow Neurological Foundation.

Source:

https://www.barrowneuro.org/

Tagged with:

About author

Related Articles